Northwest Bancshares Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.3% in the third quarter, HoldingsChannel reports. The fund owned 44,009 shares of the biopharmaceutical company’s stock after selling 590 shares during the quarter. Northwest Bancshares Inc.’s holdings in Pfizer were worth $1,581,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Evolution Wealth Advisors LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at $34,000. IMA Wealth Inc. boosted its holdings in Pfizer by 144.5% in the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 477 shares during the period. Financial Gravity Wealth Inc. boosted its holdings in Pfizer by 33.2% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 257 shares during the period. Vestor Capital LLC boosted its holdings in Pfizer by 60.1% in the 2nd quarter. Vestor Capital LLC now owns 1,547 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 581 shares during the period. Finally, HMS Capital Management LLC bought a new position in Pfizer in the 2nd quarter worth $71,000. 71.69% of the stock is owned by hedge funds and other institutional investors.

PFE stock traded up $0.29 during mid-day trading on Wednesday, hitting $35.72. The company had a trading volume of 6,610,827 shares, compared to its average volume of 24,067,033. The company has a market capitalization of $198.73 billion, a price-to-earnings ratio of 11.91, a P/E/G ratio of 2.86 and a beta of 0.66. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $46.47. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60. The company has a 50-day moving average price of $35.91 and a 200 day moving average price of $40.03.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.75 by $0.05. The business had revenue of $13.26 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The business’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.77 EPS. As a group, analysts expect that Pfizer Inc. will post 2.81 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.36 dividend. This represents a $1.44 annualized dividend and a yield of 4.03%. The ex-dividend date is Thursday, November 7th. Pfizer’s payout ratio is currently 48.00%.

Several brokerages recently weighed in on PFE. Credit Suisse Group reaffirmed a “neutral” rating on shares of Pfizer in a report on Monday, August 12th. ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. JPMorgan Chase & Co. upped their target price on shares of Pfizer from $37.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday, September 19th. They noted that the move was a valuation call. Morgan Stanley dropped their target price on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a report on Tuesday, August 27th. Finally, DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 target price for the company in a report on Wednesday, August 28th. Thirteen research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $45.25.

In other Pfizer news, Director Scott Gottlieb bought 3,000 shares of the firm’s stock in a transaction dated Friday, August 23rd. The shares were purchased at an average cost of $34.72 per share, for a total transaction of $104,160.00. Following the transaction, the director now owns 3,000 shares of the company’s stock, valued at $104,160. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Pfizer Inc bought 50,000 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $900,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is owned by insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: Special Dividends

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.